Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer. - Wikidata - awgldk - TriplyDB

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.

http://www.wikidata.org/entity/Q33432898

about

Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer.

P2860

Q47903659-B9776D86-CA8F-4B12-9A73-9A2290E49306

P2860

Continuation maintenance therapy with S-1 in chemotherapy-naïve patients with advanced squamous cell lung cancer.

http://www.wikidata.org/entity/Q33432898

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Continuation maintenance thera ...... ced squamous cell lung cancer.

@ast

Continuation maintenance thera ...... ced squamous cell lung cancer.

@en

type

label

Continuation maintenance thera ...... ced squamous cell lung cancer.

@ast

Continuation maintenance thera ...... ced squamous cell lung cancer.

@en

prefLabel

Continuation maintenance thera ...... ced squamous cell lung cancer.

@ast

Continuation maintenance thera ...... ced squamous cell lung cancer.

@en

P1433

Q33432898-AFC40BE9-F33A-47E4-9410-A2A11E7F2D1E

P1476

Q33432898-628580C1-9F81-49A0-9A8F-938C64627EB7

P2093

Q33432898-0F0A5218-6C67-478E-9008-3020BA8C3B1D

Q33432898-16F4E9A8-2742-4B3F-9EC5-CE1F2989930E

Q33432898-1F8DFC19-C478-4550-B772-82B5E7374571

Q33432898-2240CEA9-F980-45FB-B363-BCAD9C02890C

Q33432898-2A4217C5-2FAE-4CC1-828F-C74B58A4E5A0

Q33432898-2AB1AE12-EE0B-4ED7-B4FC-4580D645CBFE

Q33432898-2E609A18-DCB2-4FF3-ADE6-64E5905CDDC1

Q33432898-3B99D20C-0030-45B5-801B-A5C125DD71A9

Q33432898-47F6F7B0-0EFD-44AC-AB9F-6A53515E8543

Q33432898-57A6F68A-8825-4E8D-9097-B6888852C9AB

P2860

Q33432898-056C3888-E8D8-4B68-90C5-E5A69FC104FC

Q33432898-15C50F40-A7B1-46DD-AB83-34212BC6C03A

Q33432898-177F1ECC-C493-44B3-884F-5B32D040835A

Q33432898-1F8A1C0D-54A4-4BF6-A32D-5ED96BE270E8

Q33432898-251B6C44-1EB1-44A9-A88B-08737CBEBC4C

Q33432898-2B37AD35-B24A-41A7-9CEC-CC0455F967C0

Q33432898-41D8A84E-628C-400C-87D2-63961EBADD11

Q33432898-68467BB3-90DB-46B3-BDD5-DC8F989D1580

Q33432898-6B2369EA-D101-4EB1-9CB1-FC67D7EAF01D

Q33432898-8503F2AB-ADA9-4516-87CB-13907C48F57C

P2888

Q33432898-4BDC4B6A-CE78-447D-9292-99B81619AA9C

P304

Q33432898-79C73DE3-E71B-4488-9769-4F4CEF502CAD

P31

Q33432898-FA3C22DF-C9E0-48ED-8BC9-9BA56C39CC0E

P356

Q33432898-4E02B5CA-97CE-4FA1-B2F9-F3457CC01631

P433

Q33432898-96B56A8C-09C7-4281-B557-078AE8F9DEE8

P478

Q33432898-6AF6EA68-09F1-4EFA-962B-18FAE477C631

P577

Q33432898-8F0E9DAD-6502-48E4-A64C-BBA8853FC37C

P6179

Q33432898-FBF3BE65-D400-4B8B-AF65-56E83885E7E4

P698

Q33432898-B1E3703C-A2AF-4DDD-8387-953485F364E0

P356

S10637-016-0365-4

P1433

Investigational New Drugs

P1476

Continuation maintenance thera ...... ced squamous cell lung cancer.

@en

P2093

Hiroshi Watanabe

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Matsuda

http://www.w3.org/2001/XMLSchema#string

Kazuhiro Asada

http://www.w3.org/2001/XMLSchema#string

Koshi Yokomura

http://www.w3.org/2001/XMLSchema#string

Masafumi Masuda

http://www.w3.org/2001/XMLSchema#string

Masato Karayama

http://www.w3.org/2001/XMLSchema#string

Mikio Toyoshima

http://www.w3.org/2001/XMLSchema#string

Naoki Inui

http://www.w3.org/2001/XMLSchema#string

Naoki Koshimizu

http://www.w3.org/2001/XMLSchema#string

Noriyuki Enomoto

http://www.w3.org/2001/XMLSchema#string

P2860

2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR

Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer

Phase III trial comparing oral S-1 plus carboplatin with paclitaxel plus carboplatin in chemotherapy-naïve patients with advanced non-small-cell lung cancer: results of a west Japan oncology group study.

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010

Plasma concentrations of 5-fluorouracil and F-beta-alanine following oral administration of S-1, a dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, as compared with protracted venous infusion of 5-fluorouracil.

The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.

P2888

s10637-016-0365-4

P304

490-496

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10637-016-0365-4

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

34

http://www.w3.org/2001/XMLSchema#string

P577

2016-06-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1021623470

http://www.w3.org/2001/XMLSchema#string

P698

27279143

http://www.w3.org/2001/XMLSchema#string